Centre for Pharmacoepidemiology

The Centre for Pharmacoepidemiology (CPE) works in a dynamic environment at the intersection of academia, healthcare, authorities and the pharmaceutical industry.
We conduct academic research on drug safety, drug effectiveness and drug utilization and perform regulator-mandated Post-Authorisation Safety Studies (PASS) and Drug Utilization Studies (DUS) in the area of pharmacoepidemiology and real-world evidence (RWE).

Photo: Annika Evolahti
Aula Medica Photo: Annika Evolahti

News

Arvid Engström Photo: NA

Congratulations to Arvid on his dissertation!

We are pleased to announce that Arvid Engström successfully defended his thesis “” Beyond Glycaemic Control: SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Cardiovascular- Kidney-Metabolic Syndrome”  on June 9, 2026.

SIGMA Consortium Board meeting 2026 Photo: NA

SIGMA Consortium Board meeting

At the end of May, CPE hosted the SIGMA Consortium Board meeting with its 15 members across Europe. Discussions focused on the fast-changing environment as well as SIGMA’s continued long-term commitment to high-quality scientific research.